Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Shree Ganesh Biotech (India) Ltd approved the unaudited financial results for the quarter ended 30th June 2025 at its meeting held on 25th July 2025. Revenue from operations dropped sharply to Rs. 138.36 lacs from Rs. 355.61 lacs in the same quarter last year, a YoY decline of about 61%. Despite the steep fall in revenue, the company posted a net profit of Rs. 32.70 lacs versus Rs. 23.78 lacs in Q1 FY25, a YoY PAT growth of around 37%. Total income for the quarter stood at Rs. 179.89 lacs, and EPS was reported at Rs. 0.01. The statutory auditors (Bipin & Co.) issued a clean limited review report with no qualifications or adverse remarks.
The mismatch between falling revenue and rising profit is unusual and needs scrutiny — shareholders should watch for clarity on whether the revenue decline is temporary or reflects structural weakness. A clean auditor review and positive PAT growth are reassuring, but the steep revenue contraction could weigh on sentiment.